Loading patent…
AssigneeUniversity of Virginia Patent Foundation
InventorsRahul Sharma, Mark D. Okusa
Estimating the term…
The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.
A method for treating inflammation associated with acute kidney injury, the method comprising administering to a subject in need thereof, a pharmaceutical composition comprising an effective amount of an Interleukin-233 (IL233) fusion protein comprising a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment thereof, wherein the IL-2 domain or biologically active fragment thereof binds to IL-2 receptor, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment thereof, wherein the IL-33 domain or biologically active fragment thereof binds to IL-33 receptor, and further wherein said IL-2 domain is linked to said IL-33 domain with a linker, wherein the acute kidney injury is associated with a disease or disorder selected from the group consisting of renal ischemia reperfusion injury (IRI), lupus glomerulonephritis (GN), obesity-linked Type-2 diabetes, progression of obesity, transplant rejection, hyperglycemia, and diabetic nephropathy.
Dependencies are inferred from the claim text.